ARCT Arcturus Therapeutics, Inc.
Arcturus Therapeutics, Inc. (ARCT) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.60 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +27.2% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Arcturus Therapeutics, Inc.
Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA.
Sector
Healthcare
Industry
Biotechnology